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Abstract The spontaneously hypertensive rat (SHR) is the
most widely used animal model of essential hypertension
and associated metabolic disturbances. Multiple quantita-
tive trait loci associated with hemodynamic and metabolic
parameters have been mapped in the SHR. Recently, it has
become possible to identify some of the specific quantita-
tive trait gene (QTG) variants that underlie quantitative trait
loci linked to complex cardiovascular and metabolic traits
in SHR related strains. Recombinant inbred strains derived
from SHR and Brown Norway progenitors, together with
SHR congenic and transgenic strains, have proven useful
for establishing the identity of several QTGs in SHR
models. It is anticipated that the combined use of linkage
analyses and gene expression profiles, together with the
recently available genome sequences of both the SHR and
Brown Norway strains and new methods for manipulating
the rat genome, will soon accelerate progress in identifying
QTGs for complex traits in SHR-related strains.
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Introduction
Genome-wide association studies (GWAS) represent the
most widely used approach for genetic analyses of common
human diseases with multifactorial inheritance [1•]. The
identification of genetic variants associated with essential
hypertension has turned out to be particularly challenging.
The original GWAS (with 14,000 cases and 3000 controls),
The Wellcome Trust Case Control Consortium, revealed no
statistically significant associations between any of the
approximately 500,000 single nucleotide polymorphisms
(SNPs) and the dichotomous hypertension trait [2]. Recent-
ly, the results of two GWAS were reported, Global Blood
Pressure Genetics (Global BP Gen) Consortium [3] and
Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium [4], including
respective meta-analyses of 34,433 and 29,136 individuals
of European ancestry, with measurements of systolic and
diastolic blood pressure. Both studies identified several
SNPs in the proximity of known genes that were signifi-
cantly associated with effects on systolic or diastolic blood
pressures of less than 1 mm Hg. Notwithstanding the small
effect sizes on blood pressure, results of this kind
theoretically could point to interesting new candidate genes
that may merit further study from both mechanistic and
therapeutic perspectives. To date, however, GWAS explain
only a small portion of total heritability, and very few
publications involving GWAS have gone beyond statistical
findings to include direct experimental testing of the SNPs
to investigate their functional impact at the cellular level or to
confirm putative effects on blood pressure in vivo [5•, 6, 7].
Given the dramatic advances occurring in next-generation
sequencing technology [8], together with increasing interest
in the rare-variant hypothesis of hypertension [9], it is
possible that direct sequence analysis of thousands of
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hypertensive patients and controls may someday ultimately
supplant the use of GWAS in hypertension.
The Spontaneously Hypertensive Rat
Although results obtained in animal models of human
diseases must be interpreted with caution because of
important differences between animals and humans in
pathophysiologic processes, studies in animal models can
provide useful information about genes and pathways
underlying complex pathophysiologic traits in humans.
The spontaneously hypertensive rat (SHR) is the most
widely used animal model of essential hypertension. Under
specific environmental conditions, such as when fed a high-
fructose diet, the SHR also develops additional features of
the metabolic syndrome, including insulin resistance and
dyslipidemia [10]. As in humans, spontaneous hypertension
and associated metabolic disturbances in the SHR represent
complex, polygenic traits. Identification of responsible
genes in the SHR could be used to study the role of human
orthologous genes in complex cardiovascular and metabolic
diseases and to identify new pathways and targets for
pharmaceutical interventions [11].
Linkage analyses of crosses between the SHR and
various control strains have revealed multiple quantitative
trait loci (QTL) associated with blood pressure variation
and with parameters of lipid and glucose metabolism on
practically all rat chromosomes (see the Rat Genome
Database [12] and additional online resources [13]). Based
on stringent criteria for identifying QTL at the molecular
level, including studies in co-isogenic strains [14], only a
few of the responsible quantitative trait genes (QTGs)
underlying these QTL for blood pressure and metabolic
phenotypes have been confirmed in SHR-related models: 1)
a deletion variant of Cd36 (fatty acid translocase) has been
confirmed as a genetic determinant of multiple features of
the metabolic syndrome including dyslipidemia, insulin
resistance, and hypertension [15–17, 18•]; 2) a mutated form
of Ogn (osteoglycin) has been confirmed as a gene
predisposing to cardiac hypertrophy [19•]; and 3) a variant
in Srebf1 (sterol regulatory element binding factor 1c
isoform) has been confirmed to exert effects on hepatic lipid
levels [20]. Despite many years of intense international
effort, only one gene, Cd36, has been confirmed, using both
transgenic and congenic rescue studies, to represent a
specific molecular determinant influencing hypertension in
a model derived from the SHR [18•]. This illustrates the
inherent difficulty of identifying causative QTGs even in
animal models in which the effects of genetic background
and environmental variables can be strictly controlled.
Traditional genetic analyses in the SHR have been based
on mapping QTL in genetically segregating populations,
followed by genetic isolation of QTL in SHR congenic
strains and by positional mapping in congenic sublines.
This is a time-consuming process in which QTL are
isolated in so-called minimal congenic strains within
relatively small differential chromosome segments (usually
less than 2 Mbp). However, even minimal congenic strains
can harbor multiple genes in their differential chromosome
segments, and it is challenging to identify the responsible
QTGs within the chromosome regions of interest. For
instance, a 1.4 Mbp differential segment genetically
isolated within the SHR.PD-D8Rat42/D8Arb23 congenic
strain that differs from SHR controls in blood pressure and
sensitivity to insulin action still carries 14 genes [21]; on
the other hand, a 321 kbp segment of the SS.LEW congenic
strain with decreased blood pressure carries no evident
candidate gene [22]. Recently, however, new tools and
approaches have become available, which may help
accelerate identification of responsible gene variants that
underlie QTL isolated in SHR congenic strains. These
include 1) a combination of gene expression profiling of
tissues relevant to the pathogenesis of traits of interest
together with linkage and correlation analyses [23]; 2)
availability of the complete genome sequence of the SHR
[24••]; and 3) availability of new methods for manipulating
the rat genome, including more effective transgenesis using
Sleeping Beauty transposon vectors [25] and the possibility
of producing knockout models using embryo microinjec-
tion of zinc-finger nucleases [26] as well as techniques for
generating rat embryonic stem cells [27].
The BXH/HXB Recombinant Inbred Strains
Recombinant inbred (RI) strains are derived from F2
individuals obtained by crossing of two highly inbred strains.
Randomly chosen F2 pairs are brother-sister mated for more
than 20 generations to become genetically fixed. Individual RI
strains have unique combinations of loci derived by segrega-
tion and recombination of the alleles present in the progenitor
strains. An important feature of RI strains is that, because they
are inbred, repeated assays can be made so that phenotypes of
each strain can be more precisely estimated using average
results obtained from measurements in multiple rats per each
RI strain. A precise estimation of phenotype-genotype
relationship is especially important when studying highly
variable traits such as blood pressure or behavior. Moreover,
because data are cumulative across assays, studies, and
research groups, accumulated data can be analyzed and trait
relationships studied in a manner not possible with conven-
tional, genetically segregating populations. This is a major
advantage for the analysis of complex pathophysiologic traits.
The BXH/HXB RI strains were derived from reciprocal
crosses of the SHR/Ola and BN-Lx/Cub (Brown Norway)
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progenitors [28]. At present, 20 HXB RI strains and 10
BXH RI strains are available (F>80). The RI strains were
genotyped in over 13,000 SNPs that bin into 1,200 strain
distribution patterns [29]. In addition, over 130 copy
number variants were determined in the RI strains [30].
More than 200 physiological phenotypes determined in RI
strains are available online in the GeneNetwork database
for genetic analyses [31]. The GeneNetwork database is a
public resource that combines genomic and phenotypic
information, including gene expression profiles, with fast
software for linkage and correlation analyses [32].
The BXH/HXB RI strains were used to map the genetic
determinants of gene expression in key tissues relevant to
pathophysiology of hypertension and the metabolic syn-
drome, including kidney, retroperitoneal fat, adrenals, left
ventricles, whole brains, livers, soleus muscles, aorta, and
hypocampus [23, 33–35] (Hubner, Williams, Pravenec, et
al., unpublished results). After assessment of genome-wide
significance and accounting for multiple testing using false
discovery rates, over 1000 expression QTL (eQTL) were
found in these tissues. Linkage analyses of gene expression
profiles identified cis- and trans- acting eQTL. These
eQTL, especially cis-regulated eQTL in the vicinity of
physiological QTL (pQTL), represent a large source of
attractive candidate genes for pQTL. In addition, gene
expression profiles in relevant tissues can be correlated with
physiological traits to reveal quantitative trait transcripts
(QTT) and thus prioritize specific genes as candidates for
discovery of specific QTGs. Using this strategy, Ogn and
Cd36 genes have been identified as QTGs predisposing to
cardiac hypertrophy and hypertension, respectively [18•, 19•].
Similarly, Ephx2 (epoxide hydrolase 2, cytoplasmic) has
been identified as a genetic determinant predisposing SHHF
(spontaneously hypertensive heart failure) rats to heart failure
[36]. Gene expression profiles thus represent useful interme-
diate phenotypes between variability at the DNA level
and complex physiological traits. Additional intermediate
phenotypes, including microRNA expression, quantitative
proteome, metabonome, or epigenetic modifications
(epigenome), will be determined in the BXH/HXB RI strains
within the new integrated project EURATRANS, funded by
the European Union [37]. These new intermediate traits will
provide new levels of ever-increasing complexity, which will
enable investigators to build gene regulatory networks and
associate these with complex physiological traits.
Genome Sequence of the SHR/Ola and BN-Lx/Cub
Progenitor Strains
The BN/Mcwi strain, closely related to the BN-Lx progenitor
of the BXH/HXB RI strains, was the first completely
sequenced rat strain [38]. The other progenitor of the RI
strain data set, the SHR/Ola strain, was recently sequenced at
10.7-fold coverage using Illumina high-throughput sequenc-
ing technology (Illumina, Inc., San Diego, CA). Comparison
of the BN/Mcwi versus SHR/Ola sequences revealed
thousands of nonsynonymous SNPs and hundreds of stop
codons, frameshift mutations, and copy number variations.
All sequence variants are available in the SHRBase database
[24••]. Recently, the sequence of the BN-Lx progenitor strain
has been determined at greater than 10-fold coverage [39].
The availability of genome sequences of both progenitors of
the BXH/HXB RI strains as well as of the SHR.BN-
congenic strains that are available for most rat chromosomes
or that can be derived within a year using “supersonic“
breeding methods [40] will provide unprecedented opportu-
nities to begin systematically identifying the most promising
candidates for in vivo functional analyses and QTG isolation
at the molecular level.
Advanced Resources for Manipulating the Rat Genome
Development of Transgenic Rats Using Sleeping Beauty
Transposon Vectors
Sleeping Beauty transposon vectors have proven to be
useful tools for transgenesis. Recently, a highly active
Sleeping Beauty transposase (SB100X) was developed and
was demonstrated to be very efficient in mouse transgenesis
(about 45%) [25]. SB100X also enables a rate of trans-
genesis of approximately 25% in the SHR [41]. Transgenic
founders showed no apparent signs of mosaic transgene
Fig. 1 Transgenic spontaneously hypertensive rats (SHRs) derived
with the Sleeping Beauty RMCE/Venus transposon vectors. F1 rats
were obtained by mating the RMCE/Venus SHR line 80 with three
insertional sites on chromosomes 2, 4, and 16 with the SHR
progenitor. The different shades of green reflect segregation of the
transgenes in F1 rats (Izsvak, Mates, Landa, Pravenec, unpublished
results)
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expression and carried a few copies of the transgene.
Figure 1 shows transgenic SHRs expressing green fluores-
cent protein derived with the Sleeping Beauty transposon
system and segregation of insertional sites in transgenic
lines. Heritable and stable gene knockdown in rats has been
also achieved using RNA interference with the help of
lentiviral-mediated transgenesis [42].
Development of New Techniques
for Knocking out Specific Rat Genes
Recently, new tools for rat knockouts have become available. It
is now possible to inactivate genes using zinc finger nucleases
[26], and embryonic stem cells have been derived from rat
blastocysts [27]. These new methods should prove useful for
in vivo functional studies to analyze QTG candidates for
complex traits in the SHR and other rat models.
Variants in the Mitochondrial Genome Affect Glucose
and Lipid Metabolism
The relationship of mitochondrial DNA variants to meta-
bolic risk factors for diabetes and other common diseases
has begun to attract increasing attention. However, progress
in this area has been limited because the phenotypic effects
of variation in the mitochondrial genome are difficult to
isolate owing to confounding variation in the nuclear
genome, imprinting phenomena, and environmental factors.
Substitution of different mitochondrial genomes on the
same nuclear genetic background in conplastic strains
provides a way to unambiguously isolate effects of the
mitochondrial genome on complex traits. The SHR/Ola and
SHR/Ola-mtBN/Crl conplastic strains have identical nuclear
genomes but divergent mitochondrial genomes that encode
amino acid differences in seven proteins of oxidative
phosphorylation, including a unique phenylalanine-to-
leucine substitution in mitochondrial cytochrome c oxidase
subunit 1 (mt-Co1), as well as variants in five transfer RNA
(tRNA) genes [43]. Compared with the SHR, the conplastic
strain exhibited impaired glucose tolerance, lower skeletal
muscle glycogen and adenosine triphosphate (ATP) levels,
as well as decreases in both the activity and content of
cytochrome c oxidase in liver mitochondria. Genotyping of
43 rat inbred strains identified four haplotype groups
represented by the BN, F344, LEW, and SHR mitochon-
drial genomes [43]. Additional conplastic strains with these
haplotypes of mitochondrial DNA, including SHR/Ola-mtF344
and SHR/Ola-mtLEW, also exhibited dyslipidemia and de-
creased sensitivity of skeletal muscles to insulin action when
compared with SHR controls (Pravenec et al., unpublished
observations). These findings provide some of the first direct
evidence linking naturally occurring variation in the mito-
chondrial genome (independent of variation in the nuclear
genome and other confounding factors) to inherited variation
in known risk factors for type 2 diabetes. They also establish
that spontaneous variation in the mitochondrial genome per
se can promote systemic metabolic disturbances relevant to
the pathogenesis of common diseases.
Conclusions
During the past several years, major advances have been
made in rat genome technology, and new resources have
become available, particularly for studies in the SHR and
other rat models of hypertension [44••]. The recent
availability of the SHR genome sequence, one of the first
nonhuman mammalian genomes sequenced by short-read
sequencing, should help to further accelerate analyses of
molecular mechanisms underlying spontaneous hypertension
and related metabolic phenotypes. It is hoped that these new
tools and others will enable investigators to gain better
insight into the specific genes and mechanisms that influence
blood pressure and other complex phenotypes in the SHR
and that such results will ultimately prove relevant to our
understanding of hypertension and related cardiovascular
and metabolic disorders in humans.
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